Patents Examined by Ronald T Niebauer
-
Patent number: 11952433Abstract: The present disclosure relates to a heterochiral peptide complex, a self-assembled intermediate thereof, an alignment medium composition used for nuclear magnetic resonance spectroscopy residual dipolar coupling (NMR-RDC) measurement, which includes the same, and a method for NMR measurement for a biomolecule. Since the heterochiral peptide complex contains a ?-sheet peptide and has superior structural stability against environmental factors such as heat, acidity and ionic strength, it is applicable as an alignment medium for measuring RDC for various biomolecules.Type: GrantFiled: January 20, 2021Date of Patent: April 9, 2024Assignee: INDUSTRY ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITYInventors: Yong-Beom Lim, Hye Soo Lee
-
Patent number: 11939398Abstract: The invention relates to neurodegenerative disorders, and in particular to novel peptides, peptidomimetics, compositions, therapies and methods for treating such conditions, for example Alzheimer's disease.Type: GrantFiled: August 16, 2017Date of Patent: March 26, 2024Assignee: Neuro-Bio LtdInventors: Susan Greenfield, Sara Garcia-Rates, Jesus Seco Moral, Roger Prades Cosano
-
Patent number: 11939399Abstract: A synthetic peptide sp4 has an amino acid sequence shown in SEQ ID NO: 1. As the sole effective ingredient in the antitumor efficacy test, it has a significant inhibitory effect on both the tumor volume and tumor weight of human osteosarcoma MG-63 in nude mice and has a significant dose-effect and time-effect relationship. There is no difference between the relative tumor growth rate T/C (%) of sp4 and that of the positive control group of Paclitaxel. The safety of sp4 is that its maximal tolerated dose for intravenous administration is 700 mg/kgBW. Sp4 has clear targets of pharmacological effects, while having efficacy in vivo, it also has an inhibitory effect on tumor telomerase, has an arrest on G1 phase of the tumor cell cycle, and inhibits the high expressions of tumor PD-L1 and CD47. The present disclosure relates to multiple uses of sp4, especially in the preparation of a class of antitumor drugs.Type: GrantFiled: March 24, 2022Date of Patent: March 26, 2024Assignee: TAIAN CITY QIHANG BIOTECHNOLOGY CO.Inventors: Wanqin Zhang, Yintian Li, Xuewen Ji, Limei Zhao
-
Patent number: 11939400Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an WIC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.Type: GrantFiled: March 10, 2022Date of Patent: March 26, 2024Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
-
Patent number: 11939401Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.Type: GrantFiled: March 18, 2022Date of Patent: March 26, 2024Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
-
Patent number: 11926677Abstract: Presented herein are cancer peptide agents and uses thereof for treating cancer and/or inhibiting metastasis. Also presented herein are methods of treating cancer, or inhibiting metastasis of cancer in a subject, comprising administering a therapeutically effective amount of a composition comprising one or more cancer peptide agents to the subject. Also presented herein is a method of treating a cancer in a subject, or inhibiting metastasis of a cancer in a subject that comprises administering a therapeutically effective amount of a composition comprising one or more cancer peptide agents, and administering a chemotherapy or chemotherapeutic agent.Type: GrantFiled: October 30, 2020Date of Patent: March 12, 2024Assignee: SYMTHERA CANADA LTD.Inventor: Chai Ezerzer
-
Patent number: 11918622Abstract: Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.Type: GrantFiled: November 30, 2022Date of Patent: March 5, 2024Assignee: MAIA PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Patent number: 11912793Abstract: A polypeptide and an application thereof in bone repair are provided. An amino acid sequence of the polypeptide provided by the invention is shown as SEQ ID NO: 1. The invention further discloses use of the polypeptide GS18 in bone injury and/or bone repair. Furthermore, the invention further discloses an application of the polypeptide GS18 as well as a polypeptide scaffold for bone repair. The polypeptide of the invention demonstrates the ability to translocate ?-catenin into the nucleus and induce the expression of secreted protein osteocalcin in vivo. In vitro, the polypeptide facilitates the osteogenic differentiation of osteogenesis-oriented BMSCs (pre-osteoblasts thereby promoting the process of bone repair.Type: GrantFiled: April 28, 2023Date of Patent: February 27, 2024Assignee: SICHUAN UNIVERSITYInventors: Ling Ye, Fanyuan Yu, Jiayi Wu, Feifei Li
-
Patent number: 11912790Abstract: Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed as well as uses thereof.Type: GrantFiled: July 10, 2019Date of Patent: February 27, 2024Assignee: Immunity Pharma Ltd.Inventors: Eran Ovadia, Avi Ben-Shimon
-
Patent number: 11905536Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.Type: GrantFiled: July 30, 2021Date of Patent: February 20, 2024Assignees: GemVax & KAEL Co., Ltd.Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Bum Joon Kim, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Hwain Jang, Jung Soon Ha
-
Patent number: 11903993Abstract: Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.Type: GrantFiled: November 30, 2022Date of Patent: February 20, 2024Assignee: MAIA PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Patent number: 11897926Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.Type: GrantFiled: January 11, 2022Date of Patent: February 13, 2024Assignee: Eli Lilly and CompanyInventors: Jorge Alsina-Fernandez, Andrea Renee Geiser, Lili Guo, Samantha Grace Lyons Keyser, John Lee, Hongchang Qu, William Christopher Roell
-
Patent number: 11884746Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: April 26, 2021Date of Patent: January 30, 2024Assignee: CytomX Therapeutics, Inc.Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva
-
Patent number: 11872262Abstract: The present invention relates to non-naturally occurring anti-bacterial peptides. More specifically the peptides can be used to treat multi-drug resistant bacterial infections. In addition, the present invention provides methods for producing anti-bacterial peptides.Type: GrantFiled: May 9, 2018Date of Patent: January 16, 2024Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Joost Schymkowitz, Frederic Rousseau
-
Patent number: 11872263Abstract: The present invention relates to novel fragments of AIMP1 protein and a composition for improving alopecia and promoting hair growth comprising the same, more specifically it relates to a polypeptide consisting of 4 to 21 consecutive amino acids from the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28th to 31st amino acid residue (KEKA) of amino acid sequence of SEQ ID NO: 1, or a polypeptide consisting of an amino acid sequence having 70% or more sequence homology with the polypeptide; a polynucleotide encoding the polypeptide; a pharmaceutical, cosmetic and food composition for improving alopecia and promoting hair growth comprising the polypeptide.Type: GrantFiled: March 26, 2021Date of Patent: January 16, 2024Assignee: CUREBIO THERAPEUTICSInventors: Sunghoon Kim, Min Chul Park, Younha Kim
-
Patent number: 11866750Abstract: The present invention relates to the field of antimicrobial enzymes. In particular, the present invention relates to a polypeptide comprising an amino acid sequence exhibiting at least 90% sequence identity with the sequence of SEQ ID NO:1, with the proviso that the polypeptide does neither comprise the sequence according to SEQ ID NO:2, nor the sequence according to SEQ ID NO:3, nor the sequence according to SEQ ID NO:4. The present invention relates also to nucleic acids encoding an inventive polypeptide, vectors or bacteriophages comprising an inventive nucleic acid as well as host cells comprising an inventive polypeptide, nucleic acid, vector, and/or bacteriophage. Similarly, the present invention relates to compositions comprising a polypeptide, nucleic acid, vector, bacteriophage, and/or host cell according to the present invention.Type: GrantFiled: November 18, 2021Date of Patent: January 9, 2024Assignee: SASINAPAS CO., LTD.Inventor: Martin Griessl
-
Patent number: 11866517Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an WIC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.Type: GrantFiled: November 12, 2021Date of Patent: January 9, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
-
Patent number: 11866516Abstract: The present invention relates to an isolated peptide, an anti-cancer medicinal composition including the same and a method of specifically reducing or inhibiting activities of cancer cells using the same. The isolated peptide including a TAT basic domain conjugated to a GABARAPL2 H2 domain can specifically reduce or inhibit an activity of cancer cells, thereby being applied to the anti-cancer medicinal composition and the method of specifically reducing or inhibiting activities of cancer cells using the same.Type: GrantFiled: June 16, 2022Date of Patent: January 9, 2024Assignee: NATIONAL SUN YAT-SEN UNIVERSITYInventor: Chih-Wen Shu
-
Patent number: 11859017Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.Type: GrantFiled: March 18, 2022Date of Patent: January 2, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
-
Patent number: 11819021Abstract: Novel activators of the APC complex and methods and uses of these activators are provided. In particular, the activators are used for increasing resistance to stress and/or increasing lifespan in a plant or mammalian cell, in a plant or mammalian embryo or in a plant or subject. The activators are also used for treating cancer in a subject.Type: GrantFiled: April 4, 2018Date of Patent: November 21, 2023Assignee: University of Saskatchewan & National Research Council of CanadaInventors: Troy Harkness, Terra Gayle Arnason, Pankaj Bhowmik